AUTL vs. FDMT, TARS, ADMA, VIR, SRRK, ADAP, KYTX, BCRX, INBX, and TWST
Should you be buying Autolus Therapeutics stock or one of its competitors? The main competitors of Autolus Therapeutics include 4D Molecular Therapeutics (FDMT), Tarsus Pharmaceuticals (TARS), ADMA Biologics (ADMA), Vir Biotechnology (VIR), Scholar Rock (SRRK), Adaptimmune Therapeutics (ADAP), Kyverna Therapeutics (KYTX), BioCryst Pharmaceuticals (BCRX), Inhibrx (INBX), and Twist Bioscience (TWST). These companies are all part of the "biological products, except diagnostic" industry.
4D Molecular Therapeutics (NASDAQ:FDMT) and Autolus Therapeutics (NASDAQ:AUTL) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, community ranking, profitability, institutional ownership, valuation, dividends, risk, media sentiment and earnings.
4D Molecular Therapeutics has a beta of 2.87, indicating that its share price is 187% more volatile than the S&P 500. Comparatively, Autolus Therapeutics has a beta of 1.9, indicating that its share price is 90% more volatile than the S&P 500.
4D Molecular Therapeutics has higher revenue and earnings than Autolus Therapeutics. 4D Molecular Therapeutics is trading at a lower price-to-earnings ratio than Autolus Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, 4D Molecular Therapeutics had 11 more articles in the media than Autolus Therapeutics. MarketBeat recorded 17 mentions for 4D Molecular Therapeutics and 6 mentions for Autolus Therapeutics. Autolus Therapeutics' average media sentiment score of 0.73 beat 4D Molecular Therapeutics' score of 0.48 indicating that 4D Molecular Therapeutics is being referred to more favorably in the media.
4D Molecular Therapeutics currently has a consensus target price of $44.22, indicating a potential upside of 78.46%. Autolus Therapeutics has a consensus target price of $8.16, indicating a potential upside of 70.00%. Given Autolus Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe 4D Molecular Therapeutics is more favorable than Autolus Therapeutics.
Autolus Therapeutics has a net margin of 0.00% compared to Autolus Therapeutics' net margin of -436.30%. Autolus Therapeutics' return on equity of -34.14% beat 4D Molecular Therapeutics' return on equity.
Autolus Therapeutics received 185 more outperform votes than 4D Molecular Therapeutics when rated by MarketBeat users. Likewise, 67.08% of users gave Autolus Therapeutics an outperform vote while only 64.71% of users gave 4D Molecular Therapeutics an outperform vote.
99.3% of 4D Molecular Therapeutics shares are held by institutional investors. Comparatively, 72.8% of Autolus Therapeutics shares are held by institutional investors. 10.7% of 4D Molecular Therapeutics shares are held by company insiders. Comparatively, 25.7% of Autolus Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Summary
4D Molecular Therapeutics beats Autolus Therapeutics on 11 of the 18 factors compared between the two stocks.
Get Autolus Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for AUTL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AUTL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Autolus Therapeutics Competitors List
Related Companies and Tools
